1. Home
  2. BBDC vs PCRX Comparison

BBDC vs PCRX Comparison

Compare BBDC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBDC
  • PCRX
  • Stock Information
  • Founded
  • BBDC 2006
  • PCRX 2006
  • Country
  • BBDC United States
  • PCRX United States
  • Employees
  • BBDC N/A
  • PCRX N/A
  • Industry
  • BBDC Diversified Financial Services
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBDC Finance
  • PCRX Health Care
  • Exchange
  • BBDC Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • BBDC 1.1B
  • PCRX 1.2B
  • IPO Year
  • BBDC 2007
  • PCRX 2011
  • Fundamental
  • Price
  • BBDC $10.78
  • PCRX $25.16
  • Analyst Decision
  • BBDC Hold
  • PCRX Buy
  • Analyst Count
  • BBDC 2
  • PCRX 9
  • Target Price
  • BBDC $10.00
  • PCRX $26.22
  • AVG Volume (30 Days)
  • BBDC 474.6K
  • PCRX 805.4K
  • Earning Date
  • BBDC 02-20-2025
  • PCRX 02-27-2025
  • Dividend Yield
  • BBDC 6.21%
  • PCRX N/A
  • EPS Growth
  • BBDC N/A
  • PCRX N/A
  • EPS
  • BBDC 1.04
  • PCRX N/A
  • Revenue
  • BBDC $286,169,000.00
  • PCRX $694,957,000.00
  • Revenue This Year
  • BBDC $0.48
  • PCRX $5.55
  • Revenue Next Year
  • BBDC N/A
  • PCRX $5.64
  • P/E Ratio
  • BBDC $10.37
  • PCRX N/A
  • Revenue Growth
  • BBDC N/A
  • PCRX 4.40
  • 52 Week Low
  • BBDC $8.96
  • PCRX $11.16
  • 52 Week High
  • BBDC $10.82
  • PCRX $31.67
  • Technical
  • Relative Strength Index (RSI)
  • BBDC 83.66
  • PCRX 52.48
  • Support Level
  • BBDC $10.05
  • PCRX $25.41
  • Resistance Level
  • BBDC $10.16
  • PCRX $26.89
  • Average True Range (ATR)
  • BBDC 0.13
  • PCRX 1.18
  • MACD
  • BBDC 0.05
  • PCRX -0.36
  • Stochastic Oscillator
  • BBDC 95.45
  • PCRX 4.35

About BBDC Barings BDC Inc.

Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. Barings employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Share on Social Networks: